Virus therapy takes on brain cancer in early trial
NCT ID NCT03152318
First seen Mar 04, 2026 · Last updated Jun 15, 2026 · Updated 13 times
Summary
This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. The virus is designed to attack tumor cells, and some participants also receive a drug called cyclophosphamide to help the immune system respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Johns Hopkins University Medical Center
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.